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The osteoprogenitor-specific loss of 
ephrinB1 results in an osteoporotic 
phenotype affecting the balance 
between bone formation and 
resorption
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Andrew C. W. Zannettino  2,3 & Stan Gronthos  1,2
The present study investigated the effects of conditional deletion of ephrinB1 in osteoprogenitor cells 
driven by the Osterix (Osx) promoter, on skeletal integrity in a murine model of ovariectomy-induced 
(OVX) osteoporosis. Histomorphometric and μCT analyses revealed that loss of ephrinB1 in sham 
Osx:cre-ephrinB1fl/fl mice caused a reduction in trabecular bone comparable to OVX Osx:Cre mice, 
which was associated with a significant reduction in bone formation rates and decrease in osteoblast 
numbers. Interestingly, these observations were not exacerbated in OVX Osx:cre-ephrinB1fl/fl mice. 
Furthermore, sham Osx:cre-ephrinB1fl/fl mice displayed significantly higher osteoclast numbers and 
circulating degraded collagen type 1 compared to OVX Osx:Cre mice. Confirmation studies found 
that cultured monocytes expressing EphB2 formed fewer TRAP+ multinucleated osteoclasts and 
exhibited lower resorption activity in the presence of soluble ephrinB1-Fc compared to IgG control. This 
inhibition of osteoclast formation and function induced by ephrinB1-Fc was reversed in the presence 
of an EphB2 chemical inhibitor. Collectively, these observations suggest that ephrinB1, expressed by 
osteoprogenitors, influences bone loss during the development of osteoporosis, by regulating both 
osteoblast and osteoclast formation and function, leading to a loss of skeletal integrity.
The Eph/ephrin molecules originally identified in the hematopoietic system1 have subsequently been implicated 
in numerous developmental and pathophysiological processes2–5. Importantly, members of both subclasses 
have been associated with skeletal development and bone homeostasis, with particular focus on the signalling 
between EphB4/ephrinB2 and EphB2/ephrinB1 interacting pairs6–12. Pioneering studies in mouse proposed that 
bi-directional signalling between EphB4 expressing osteoblasts and ephrinB2 expressing osteoclast precursors 
promoted mineral formation, while inhibiting osteoclast formation and function, respectively6,9. Importantly, 
these EphB/ephrinB interactions are not limited to the communication between osteoblasts and osteoclasts, as 
ephrinB ligands are also expressed by osteoblasts and osteocytes6; and can act on neighbouring osteogenic cells, 
to influence osteoblast formation and function7,10,11. In vitro studies assessing human mesenchymal stem cell 
populations demonstrated the expression of multiple Eph/ephrin molecules, and identified EphB2/ephrinB inter-
actions as important promoters of mineral formation4,5,8. Other studies have demonstrated that biomechanical 
loading caused an elevation in EphB2 expression in wild type mice when compared to un-loaded conditions13,14, 
with similar observations reported for ephrinB1 over-expressing transgenic mice15. Notably, EphB4 expression 
was unchanged in these studies, suggesting that in situations of active bone remodelling, mineralisation may 
occur through EphB2/ephrinB1 interactions independently of EphB4/ephrinB2.
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Human mutations of ephrinB1 cause skeletal defects, of both the axial and appendicular skeleton, particularly 
coronal craniosynostosis and frontonasal dysplasia, in addition to asymmetrical lower limb shortness16–18. In 
mouse, global knockout19,20 of ephrinB1 or deletion within osteogenic populations, under the control of col-
lagen type 1 promoter21 or Osterix promoter12, also result in skeletal defects similar to the human phenotype. 
Conversely, ephrinB1-overexpressing transgenic mice demonstrate an elevation in bone mass and strength15. 
Collectively these observations suggest that ephrinB1 has an important role skeletal formation, where the loss 
of ephrinB1 in osteoprogenitors during skeletal development perturbed osteoblast formation and function, and 
osteoclast formation12, by an undetermined mechanism. This observation suggests that, while ephrinB1 may be 
communicating with adjacent EphB expressing osteogenic cells, direct or indirect communication may occurs 
between osteoblasts and osteoclasts, to influence bone homeostasis. The importance of ephrinB1 in skeletal 
homeostasis is also evident in pathological situations. This molecule has been associated with the pathogenesis 
of osteosarcoma, where ephrinB1 expressed by osteosarcoma cells and blood vessels, associated with a poorer 
prognosis22. Furthermore, during lactation-induced maternal bone loss, ephrinB1 expression was upregulated, 
while EphB4 and ephrinB2 expression remained unaltered23.
Collectively, these studies suggest that ephrinB1 may play an important role in bone disease and could act 
as an important regulator in maintaining bone homeostasis. However, to date, little is known about the role of 
ephrinB1 in the context of dysregulated bone homeostasis, as occurs with osteoporosis. The present study investi-
gated the importance of ephrinB1 expressed by the osteogenic cell lineage to maintain skeletal integrity in mature 
mice following ovariectomy-induced osteoporosis.
Materials and Methods
All methods were performed in accordance with the relevant Institutional (Adelaide University) and Australian 
Federal Government guidelines and regulations. Animal breeding and experiments approved by the SA Pathology 
(BC BC01/11 and 23/11) and the University of Adelaide Animal Ethics Committee (M-2013-144). Human blood 
samples were isolated from normal healthy donors with informed consent, in accordance to the guidelines and 
regulations of the Royal Adelaide Hospital Human Ethics Committee (protocol No. 940911a).
Animal Breeding and surgery. Animal breeding was approved by the SA Pathology (BC BC01/11) Animal 
Ethics Committee. All animal experiments and analyses were approved by both SA Pathology (23/11) and the 
University of Adelaide (M-2013-144) Animal Ethics Committees. The tTA:Osx1-GFP:Cre (hereafter referred to 
as Osx:Cre) mice24 were used to conditionally delete ephrinB1 in osteogenic progenitors25, where Osx:Cre targets 
stromal cells, adipocytes and perivascular cells within the bone marrow. External to the skeletal system Osx:Cre 
has also been shown to target a subset of cells within the gastric and intestinal epithelium and the olfactory 
bulb26,27. To delete ephirnB1 in osteogenic progenitors, breeding was performed as previously described12. Briefly, 
129S-Efnb1tm1Sor/J (EfnB1fl/fl) female mice (JAX Laboratories, Bar Harbor, Me, USA) that had been backcrossed 
for 10 generations to a C57BL/6 genetic background, were bred with Osx:Cre males to obtain Osx:cre-EfnB1fl/0 
males. These males were bred with EfnB1fl/fl females to obtain homozygote Osx:cre-EfnB1fl/fl females in the osteo-
blast lineage (hereafter referred to as EfnB1OB−/−). Twelve week old C57BL/6 female Osx:Cre or EfnB1OB−/− mice 
were anesthetised, there ovaries were either sited (sham control) or were ovariectomised (OVX). The animals 
had their dorsal skin sutured and were allowed to recover under normal housing conditions and food and water 
were provided ad libitum. Calcein (20 mg/kg) was administered by intraperitoneal injection 10 and 3 days prior 
to tissue collection. Samples were analysed at 12 weeks post-surgery.
Micro-CT (μCT) scanning and analysis. Three-dimensional micro computed tomography (µCT) was per-
formed as previously outlined of the femur12 and the fifth lumbar vertebrae28 using Micro-CT (femur -Skyscan 
1076× -ray Microtomography SkyScan, Vertebrae - Skyscan 1176× -ray Microtomography SkyScan Bruker 
Microct, Kontich, Belgium). Briefly, femora isolated from sham and OVX mice were scanned at 9 µm resolution, 
Aluminium 0.5 mm filter, Excitation 5890 ms, Voltage 48 kV, Current 110 mA, rotation step 0.6 and two frame 
averaging. Vertebrae were scanned at 9 µm resolution, Aluminium 0.5 mm filter, Excitation 1100 ms, Voltage 
75 kV, Current 196 mA, rotation step 0.8 and one frame averaging. NRecon software was used to reconstruct 
the femora and vertebrae, parameters were set as follows: smoothing of 1, selection of ring artefact reduction 
and beam-hardening of 30%, Threshold was set to 0–0.10 (femur) and 0–0.05 (vertebrae). Reconstructed bones 
were aligned in the same orientation using DataViewer software and then analysed using CTAn software. The 
femur were analysed by avoiding the primary spongiosa (0.43 mm below the growth plate), the trabecular region 
(1.73 mm) of the distal femora was traced as the region of interest (ROI) and analysed. The vertebral body of the 
fifth lumbar vertebrae was analysed as previously described28. Briefly, the transverse orientation was acquired, the 
entire vertebral body was traced within 0.3 mm below and above the end-plates of the vertebrae. The thresholding 
was consistent between samples. CTVol Software (SkyScan) was used to generate 3D models.
Histology. Sample preparation and staining. Femora were fixed in 10% buffered formalin for 48 hours, infil-
trated and embedded in methyl methacrylate (Merk Millipore, Vic, AUS). Samples were sectioned (5 μm) as 
previously described9 and mounted on gelatine coated super frost plus slides. Longitudinal sections were stained 
with either Toluidine blue or Tartrate Resistant Acid Phosphatase (TRAP) and counterstained with fast green, 
as previously described9. Paraffin embedded tibial 5μm sections were rehydrated and mounted in Faramount 
aqueous mounting media (DAKO). Collagen fibres were visualised using multiphoton and second harmonic 
generation imaging (Leica TCS SP8MP multiphoton microscope), with an excitation of 880 nm and emission at 
440 nm, as previously described29. Images were processed using Fiji/Image J software30.
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Histomorphometric Analysis. OsteoMeasure V3.3.02 (Osteometric, Decatur, GA) software with an Olympus 
DP72 Microscope (Notting Hill, Victoria, AUS) was used for histomorphometric analyses of longitudinal sec-
tions. The trabecular bone 40x magnification images below the primary spongiosa and avoiding regions in con-
tact with the cortical bone were analysed, in a 0.72 mm2 region for Calcein, and 0.96 mm2 region for Toluidine 
Blue and TRAP+ osteoclasts analysis. Bone formation rate was determined by measuring the distance between the 
two mineralisation fronts that were labelled with Calcein and analysed with OsteoMeasure software.
Flow cytometric analysis. Flow cytometric analysis of osteogenic populations was performed as previously 
described31–33. Briefly, compact bone was obtained by crushing the femora and tibiae, washed with PBS + 2%FCS, 
and then crushed fractions were cut into small fragments and enzymatically digested with collagenase type I 
(400 U/mL) and DNase I (50 U/mL) for 45 min at 37 °C, while shaking. Cells were washed, filtered through a 
70 μm strainer and centrifuged for 10 min at 800 g. Resuspended cells together with flushed bone marrow were 
incubated in mouse gamma globulin, washed and stained with biotinylated lineage-specific antibodies. Flow 
cytometric analysis was performed on BD LSR Fortessa X20 (BD Biosciences). The frequency of osteoblasts 
(Lin−CD45−CD31−Sca-1−CD51+), and osteoprogenitor (Lin−CD45−CD31−Sca-1+CD51+) was determined 
using FlowJo software (University of Washington, WA) as previously described(26–28).
Analysis of bone turnover serum markers. Mice were anesthetised and blood serum samples collected following 
cardiac puncture. The levels of circulating CTX-1 was analysed using RatLaps CTX-I EIA ELISA (AC-06F1; ids) 
as recommended by the manufacturer (Immunodiagnostic Systems, Boldon Business Park, UK).
RNA isolation. RNA isolation, cDNA synthesis and real time PCR were conducted as previously described32, 
using β-actin and human-specific B subclass Eph primers4,5; and Cathepsin K (NC_018912.2 Fwd: 5′-GGCCAAC 
TCAAGAAGAAAACTG-3′, Rev: 5′-TCTCTGTACCCTCTGCATTTAGC-3′); c-fms (NM_005211 Fwd: 5′-AGCTT 
GGCATGGTCAGGGAA-3′, Rev: 5′-GAAGGTAGCGTTGTTGGTGC-3′); RANK (NM_003839 Fwd: 5′-GCTGTA 
ACAAATGTGAACCAGGA-3′, Rev: 5′-GCCTTGCCTGTATCACAAACT-3′); CXCR4 (NM_003467 Fwd: 
5′-CAGCAGGTAGCAAAGTGACG-3′, Rev: 5′-GTAGATGGTGGGCAGGAAGA-3′); ephrinB1 (Fwd 5′ 
AACAAGCCACACCAGGAAAT 3′, Rev 5′ GCTCCCATTGGACGTTGAT 3′).
Osteoclast differentiation and resorption assays. Osteoclast Differentiation In Vitro: Human peripheral blood 
mononuclear cells (hPBMNC) were isolated from buffy coats from normal healthy donors. All experiments were 
performed with informed consent from each donor, in accordance with relevant guidelines and regulations of 
the Royal Adelaide Hospital Human Ethics Committee (protocol No. 940911a) as previously described34. The 
cells were seeded (0.5 × 106 per 0.32 cm2) and cultured overnight in osteoclast basal media (Minimum Essential 
Medium Alpha Modified (Sigma), 10% foetal calf serum (FCS), 1% penicillin streptomycin, 1% l-glutamine) and 
25 ng/ml macrophage colony stimulating factor (M-CSF) (Miltenyi Biotec, NSW, AUS) (Day -1) in 96-well plates 
(TRAP staining and viability analysis) or Corning Osteo Assay Surface Muliple Well plates (Sigma) (resorption 
analysis). The following day, the Human IgG-Fc or ephrinB1-Fc at 1 µg/ml (R&D systems) were pre-clustered 
with biotinylated anti-goat IgG (Jackson ImmunoReseaarch, West Grove, PA, 2.4 mg/ml) in osteoclast media 
(osteoclast base media supplemented with 25 ng/ml M-CSF, 10−8M dexamethasone (Hosporia Aust. Mulgave, 
Vic, Aust.), and 10−8M 1α,25-dihydroxyvitaminD3 (Cerilliant Corporation, TX) for 1 hour at room temperature 
prior to being added to osteoclast cultures. Media was changed three-times per week. From day 7, osteoclast 
media was also supplemented with 50 ng/ml RANKL (Miltenyi Biotec). On day 14, wells were processed for either 
RNA isolation or TRAP staining using the Sigma Acid Phosphate, Leukocyte (TRAP) kit (Sigma).
Bone marrow (BM) cells flushed from the femur and tibia of mice were cultured overnight, then non-adherent 
cells were collected and seeded (3.1 × 105 cells/cm2) in α-MEM supplemented with 75 ng/ml of M-CSF (GF053; 
Merck Millipore) and RANKL (GF091; Merck Millipore). Medium was replaced every 3 days. On day 6, RNA was 
isolated, cDNA synthesised, and qPCR performed.
EphB2 Inhibitor Assays: Human hPBMNC were incubated for 1 hour in half the final volume of osteoclast 
media (outlined above) containing 100 µM blocking peptide specific for EphB2 (SNEWILPRLPQH) or con-
trol peptide (RTVAHHGGLYHTNAEVK) (Mimotopes, Vic, Aust.). During this 1-hour incubation 2 µg/ml of 
ephrinB1-Fc (final concentration, 1 µg/ml) was clustered (outlined above) in the other half of the final volume of 
osteoclast media. The remaining 100 µM blocking peptide (SNEW or RTVA) was then combined with the clus-
tered ephrinB1-Fc. This ephrinB1-Fc-blocking peptide osteoclast media was immediately added to hPBMNC 
that had been incubated with the blocking peptide. Media changes with ephrinB1-Fc and blocking peptides were 
carried out as outlined above.
Cell Viability Assays: On day 3 and 7 following osteoclast induction, viability and metabolism were assessed 
by WST-1 (Sigma). Briefly, WST-1 was diluted in Pheno-Red free alpha-modification media (Sigma) containing 
25 ng/ml M-CSF. Cells and control blank wells were incubated with the diluted WST-1 for 1 hour at 37 °C, after 
which time the absorbance was read at 450 nm. Experimental values were normalised to the blank. On day 21, 
cells in the Corning Osteo Assay Surface Multiple Well plates were lysed with 6% sodium hypochlorite, washed 
with water three times and then left to dry. Whole wells were imaged and analysed with Image J software.
Osteogenic Differentiation In Vitro. Bone derived mesenchymal stromal cells isolated from murine tibia and 
femora were cultured in αMEM supplemented with 20% (v/v) FCS, 2 mM l-glutamine, 1 mM sodium pyru-
vate, 10 mM HEPES buffer, 50 U/ml penicillin, 50 μg/ml streptomycin, 100 µM l-ascorbate-2-phosphate (Wako 
Pure Chemical Industries, Richmond, VA, USA), 10 nM dexamethasone (RAH688A; Royal Adelaide Hospital, 
Adelaide, SA, Australia), and 4 mM KH2PO4 (Asia Pacific Specialty Chemicals Limited, Seven Hills, NSW, 
Australia). Cultures were stained with Alizarin red (A5533-25G; Sigma-Aldrich) to identify mineral deposits. 
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Extracellular calcium (Ca2+) was measured by Calcium Arsenazo III (TR29226; Thermo Fisher Scientific) and 
normalized to DNA per well with a PicoGreen dsNDNA quantitation kit (P11496; Thermo Fisher Scientific). This 
analysis was conducted in triplicate for each mouse.
Statistical analysis. Microsoft GraphPad Prism 5 (La Jolla, CA) was used for data and statistical analysis. Student 
t-test, one-way ANOVA with multiple comparisons and two-way ANOVA, using a Tukey’s multiple comparisons 
post-hoc test was used throughout the study as specified. Statistical significance is represented as p ≤ 0.05.
Results
Confirmation of osteogenic-specific deletion of ephrinB1 in EfnB1OB−/− mice. It has previously 
been reported that the deletion of ephrinB1 under the control of the Osterix promoter impairs endochondral 
ossification, compromising skeletal development and integrity12. The study demonstrated that ephrinB1 gene 
and protein levels were significantly reduced in a heterogeneous population of cultured osteogenic cells isolated 
from Osx:Cre and EfnB1OB−/− mice12. The present study confirmed that following osteogenic differentiation of 
osteogenic cells isolated from Osx:Cre and EfnB1OB−/− mice, there was a significant reduction in the formation 
of mineral nodules and extracellular calcium levels in osteogenic cells isolated from EfnB1OB−/−mice when com-
pared to Osx:Cre controls (Supplementary Fig. 1A,B). This observation correlated with a significant reduction in 
ephrinB1 gene expression in stromal cells isolated from EfnB1OB−/− mice following osteogenic induction when 
compared to the Osx:Cre control (Supplementary Fig. 1C). Furthermore, to demonstrate that the Osterix-Cre 
promoter was active specifically within the stromal population within the skeleton, marrow cells flushed from 
the long bones were placed under osteoclastic differentiation conditions. Following 6 days in osteoclast inductive 
conditions, ephrinB1 gene expression levels were found to be comparable in osteoclasts/monocyte populations 
isolated from Osx:Cre control and EfnB1OB−/− mice (Supplementary Fig. 1D–F). These observations confirmed 
that ephrinB1 under the control of the Osterix-Cre promotor was regulated in the osteogenic cell lineage and not 
the haematopoietic population within the bone marrow.
The loss of ephrinB1 in osteoprogenitors is sufficient to induce an osteoporotic bone phenotype. 
We investigated whether ephrinB1, expressed by cells of the osteogenic lineage contributed to bone remodelling 
using a model of ovariectomy (OVX)-induced osteoporosis. Ovariectomy or sham surgery was performed on 
female homozygote EfnB1OB−/− mice, or Osx:Cre control mice and skeletal parameters were assessed at 12 weeks 
post-surgery. Three dimensional µCT analysis revealed that OVX induced an osteoporotic phenotype, as evidenced 
by a significant reduction in bone to tissue volume and trabecular number in both the femora (Fig. 1A–F), and 
vertebra (Fig. 1I–N) in OVX Osx:Cre mice compared to sham Osx:Cre. Interestingly, the loss of ephrinB1 in sham 
EfnB1OB−/− mice resulted in a skeletal phenotype comparable to the OVX Osx:Cre mice, which was not further 
exacerbated following OVX in EfnB1OB−/− mice, that was observed in both the femora and the vertebra (Fig. 1). 
A significant increase in trabecular separation was observed in the femora of OVX Osx:Cre mice compared to 
sham Osx:Cre (Fig. 1C), however, this was not maintained in the vertebrae (Fig. 1K). Notably, a significant increase 
in trabecular separation within the vertebrae was observed between sham Osx:Cre and sham EfnB1OB−/− mice, 
while OVX EfnB1OB−/− mice did not reach statistical significance. Furthermore, there was no significant differ-
ence observed in the trabecular thickness between any of the cohorts (Fig. 1D,L). Confirmatory 2D histomor-
phometric analysis of toluidine blue stained sections of trabecular regions within the distal femora, showed a 
significant reduction in bone to tissue volume, trabecular number and significant increase trabecular separation 
of OVX-induced Osx:Cre control mice when compared to sham-treated Osx:Cre control mice. Consistent with the 
µCT analysis, there was no significant difference in trabecular thickness between any of the groups. Furthermore, 
homozygote sham and OVX EfnB1OB−/− mice displayed a similar phenotype to OVX-induced Osx:Cre mice 
(Fig. 2). Multiphoton and second harmonic generation imaging demonstrated that the perturbation in trabecular 
architecture was not due to an abnormal pattern of collagen type I deposition (Fig. 2A’–D’). Taken together, these 
observations suggest that ephrinB1 deletion in osteogenic cells can recapitulate an osteoporotic phenotype that 
cannot be further exacerbated by the oestrogen deprivation that accompanies OVX.
Osteoblast maturation and function is compromised by the loss of ephrinB1. Flow cytometric 
analysis was performed as previously described31–33, to enumerate the incidence of cells of the osteogenic lineage 
in the femora and tibiae of sham EfnB1OB−/− homozygote females and sham and OVX Osx:Cre mice (Fig. 3A–C). 
While there was a reduction in the osteogenic progenitors (Sca-1+/Lin−/CD31−/CD45−/CD51+) population 
between Osx:Cre and EfnB1OB−/− samples, this did not reach significance (Fig. 3A). However, there was a signif-
icant reduction in the proportion of osteoblasts (Sca-1−/Lin−/CD31−/CD45−/CD51+) between sham Osx:Cre 
mice and both sham and OVX EfnB1OB−/− mice (Fig. 3B). These findings were consistent with an observed 
reduction in the bone formation rate of OVX Osx:Cre mice, compared to sham Osx:Cre mice, and compared to 
both sham and OVX EfnB1OB−/− mice (Fig. 3C–G). These observations suggest that the cell-autonomous loss of 
ephrinB1 in osteogenic progenitors inhibits osteogenic maturation and function.
Osteoclast formation and function is affected by EphB2 forward signalling. To determine if oste-
oclast formation and activity is EphB2 dependent, and therefore affected in response to the loss of ephrinB1 by 
osteoprogenitors and mature osteogenic populations, methacrylate embedded sections were stained with TRAP, 
and the number of TRAP + multinucleated osteoclasts were enumerated within the trabecular region of the distal 
femora of sham and OVX mice (Fig. 4A–F). Twelve weeks post-surgery, OVX Osx:Cre mice presented with sig-
nificantly greater numbers of TRAP+ osteoclasts per bone perimeter compared to sham Osx:Cre mice (Fig. 4E). 
Similarly, sham EfnB1OB−/− mice displayed comparable numbers of TRAP + osteoclasts to OVX Osx:Cre mice, 
while OVX EfnB1OB−/− mice displayed significantly more TRAP + osteoclasts when compared to OVX Osx:Cre 
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mice (Fig. 4E). The proportion of osteoclast surface to bone surface was significantly greater in OVX Osx:Cre 
mice compared to sham Osx:Cre mice. However, the osteoclast surface to bone surface was comparable between 
sham and OVX EfnB1OB−/− mice; and OVX Osx:Cre mice (Fig. 4F). These data suggest that the loss of ephrinB1 
Figure 1. The loss of EfnB1 in osteoprogenitors alone induces an osteoporotic bone phenotype. (A–P) µCT 
analysis of the trabecular region of the (A–D) distal femoral and (I–L) fifth lumbar vertebral body of Osx:Cre 
(Osx) and EfnB1OB−/− (EfnB1) mice that had undergone sham or ovariectomy (OVX) surgery; represented as 
(A,I) Bone to tissue volume (BV/TV), (B,J) trabecular number (Tb.N), (C,K) trabecular separation (Tb.Sp) 
and (D,L) trabecular thickness (Tb.Th). (E–H,M–P) Representative images of 3D µCT from the (E–H) femur 
(in cross-sectional (top) and longitudinal (bottom) orientation) and (M–P) vertebral body of (E,G,M,O) sham 
and (F,H,N,P) ovariectomised (OVX) mice. All statistical analysis performed by 2-way ANOVA, multiple 
comparisons, n = 6–9 mice/condition/strain, *p < 0.05.
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within osteoprogenitor and mature osteogenic populations influences osteoclast formation. To determine if oste-
oclast function was also altered due to the loss of ephrinB1, serum samples were used to investigate circulating 
levels of degraded collagen type 1. A significant increase in circulating degraded collagen type 1 (CTX-1) was 
identified in OVX Osx:Cre mice, and both sham and OVX EfnB1OB−/− mice, when compared to sham Osx:Cre 
control mice (Fig. 4G). Importantly, ephrinB1 gene expression was similar between EfnB1OB−/− and Osx:Cre mice 
(Supplementary Fig. 1D). These findings suggest that ephrinB1 expressed by the osteogenic population affects 
osteoclast formation and function rather than in a cell-autonomous manner.
In vitro osteoclastogenesis studies were conducted to determine the direct role of ephrinB1 during human 
osteoclast formation. Gene expression analysis confirmed osteoclast differentiation of Human peripheral blood 
mononuclear cells (hPBMNC) with increasing expression levels of CathepsinK during osteoclastogenesis 
(Fig. 5A). Moreover, profiling of the Eph receptors identified that the cognate ephrinB1 receptor, EphB2, was the 
most highly expressed EphB receptor identified on hPBMNC during osteoclast differentiation (Fig. 5B). As the 
Figure 2. The loss of EfnB1 by osteoprogenitors alone impairs trabecular bone architecture similar to 
ovariectomised mice. (A–D) Representative toluidine blue stained sections of (A,B) Osx:Cre (Osx) control 
and (C,D) EfnB1OB−/− (EfnB1) femora, 12 weeks following (A–C) sham and (B–D) ovariectomy (OVX) 
surgery. (A’–D’) Representative images of collagen type I fibres. (E–H) Histomorphometric analysis of the 
trabecular region of the distal femora post-surgery represented as (E) percentage of bone to tissue volume, (F) 
trabecular number, (G) trabecular separation, and (H) trabecular thickness. All statistical analysis performed 
by 2-way ANOVA, multiple comparisons, *p < 0.05, n = 3–5 samples/strain/condition. Magnification A-D and 
A’–D’ = 10 µM.
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mouse studies demonstrated that loss of ephrinB1 by osteoprogenitors enhanced osteoclast formation, functional 
studies were conducted to confirm whether stimulation of hPBMNC with ephrinB1 alone, could inhibit osteo-
clast differentiation. Human PBMNC were cultured under osteoclastogenic conditions in the presence of either 
soluble ephrinB1-Fc or the human IgG control. The data showed that ephrinB1-Fc significantly inhibited TRAP+ 
multinucleated osteoclast formation (Fig. 5C,D). Consistent with these findings, osteoclast bone resorption activ-
ity was significantly inhibited, in the presence of soluble ephrinB1-Fc (Fig. 5E,F). Importantly, the presence of 
ephrinB1-Fc did not influence cell viability or metabolism during osteoclast formation, as demonstrated by no 
change in amount of formazan dye formed following incubation with tetrazolium salt, WST-1 (Supplementary 
Fig. 2).
To confirm that ephrinB1 was blocking osteoclast formation and function through the EphB2 receptor, inhib-
itor studies were conducted utilising the EphB2 specific blocking peptide (SNEW). SNEW specifically binds to 
the ligand binding cleft of EphB2, competing with ephrin ligand binding35. Human PBMNC cultured under 
osteoclastogenic conditions were incubated with SNEW or a scrambled peptide control (RTVA) prior to cul-
turing with ephrinB1-Fc. The competitive binding of SNEW to EphB2 in the presence of ephrinB1 significantly 
ameliorated TRAP+ osteoclast formation (Fig. 5G,H) and resorption (Fig. 5I,J) when compared to the scrambled 
control peptide (RTVA). This observation confirms that ephrinB1 interaction with EphB2 expressing osteoclast 
precursors inhibits osteoclast formation and subsequently function. Furthermore, supportive gene expression 
studies showed that transcript levels of osteoclast associated factors, Cathepsin K, c-fms, RANK and CXCR4 were 
significantly decreased during osteoclastogenesis in the presence of soluble ephrinB1 (Fig. 5K–N). These obser-
vations suggest that ephrinB1 binding, through the EphB2 receptor, inhibits osteoclast formation.
Discussion
In the present study, targeted deletion of ephrinB1, under the control of the osterix promoter, induced an osteo-
porotic phenotype in sham treated EfnB1OB−/− mice, which was comparable to that observed in OVX Osx:cre 
control mice. Notably, the osteoporotic phenotype was not exacerbated in EfnB1OB−/− mice following OVX. We 
observed a significant reduction in trabecular bone between OVX Osx:Cre mice compared to sham Osx:Cre con-
trols. The loss of ephrinB1 in sham operated EfnB1OB−/− mice resulted in a similar trabecular architecture to OVX 
induced Osx:Cre and EfnB1OB−/− mice, as demonstrated by μCT analysis of two independent sites, the femur and 
the fifth lumbar vertebrae, and histomorphometric analyses of the femur. The formation of type I collagen fibres 
is essential for skeletal architecture and integrity, where interactions of Eph family members with the extracellu-
lar matrix can influence extracellular matrix organisation36,37. However, the present study failed to observe any 
noticeable differences in the patterns of collagen deposition between Osx:Cre controls and EfnB1OB−/− mice. 
Additionally, measurement of oestrogen levels in serum failed to detect any changes in oestrogen levels (data 
Figure 3. The loss of EfnB1 by osteoprogenitors inhibits osteoblast maturation and bone formation rate. 
(A,B) Fluorescent cytometric analysis of the percentage of (A) osteoprogenitors (OP, Sca-1+/Lin−/CD31−/
CD45−/CD51+), and (B) osteoblasts (OB, Sca-1−/Lin−/CD31−/CD45−/CD51+), isolated from flushed and 
digested femora and tibia of Osx:Cre and EfnB1OB−/− sham and ovariectomised (OVX) mice 12 weeks post-
surgery (n = 5–6 samples/strain/condition). (C) Bone formation rate (BFR) was analysed by Calcein labelling 
(n = 3–5 samples/strain/condition) (D–G) Representative double labelled Calcein images. All statistical analysis 
performed by 2-way ANOVA, multiple comparisons, *p ≤ 0.05. Magnification D–G = 5 µM.
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not shown) to explain the difference observed in skeletal architecture between sham EfnB1OB−/− mice. However, 
the reduction in trabecular bone observed between OVX Osx:Cre mice, OVX EfnB1OB−/− mice and sham 
EfnB1OB−/− mice was associated with a significant reduction in bone formation rate within the femur. As the 
Osx:Cre mouse line has been reported to exhibit changes in skeletal parameters, including cortical bone augmen-
tation and accrual38, the present study utilized Osx:Cre mice rather than EfnB1fl/fl mice as the control. Therefore, 
the osteoporotic-like phenotype observed in sham EfnB1OB−/− mice did not appear to be a consequence of the 
Osx:Cre background, but rather due to deletion of ephrinB1 in osteogenic cells, which could not be exacerbated 
following OVX.
The importance of ephrinB1 in skeletal formation can be observed in individuals who display cranial and 
skeletal defects and harbour functional mutations in the ephrinB1 gene16–18. Similar skeletal abnormalities have 
been reported in global and targeted deletion of ephrinB1 during murine development12,19–21. At the molecular 
level, ephrinB1 mediates mineral formation by activating Osterix expression21. EphB2 activation of ephrinB1 
reverse signalling results in the dephosphorylation of TAZ from its complex with the PDZ domain of ephrinB1, 
PTPN13 and NHERF1. The dephosphorylated TAZ translocates to the nucleus and induces osterix expression, 
osteogenic differentiation and subsequently mineral production21. Consistent with these observations, human 
studies have shown that ephrinB1 is the most highly expressed EphB ligand on human BMSC, and activation of 
ephrinB1 promotes BMSC osteo/chondrogenic differentiation in vitro5. Flow cytometric analysis found a trend 
of lower numbers of osteoprogenitors but significantly reduced osteoblast numbers in both the sham and OVX 
Figure 4. The loss of EfnB1 by osteoprogenitors influences osteoclast formation and function. (A–D) 
Representative methacrylate embedded sections of the distal femora from (A,B) sham and (C,D) 
ovariectomised (OVX) (A,C) Osx:Cre (Osx) control and (B,D) EfnB1OB−/− (EfnB1) mice 12 weeks post-surgery 
stained with TRAP. (E,F) Histomorphometric analysis quantitating (E) the number of TRAP+ osteoclasts lining 
the bone perimeter, and (F) the percentage of osteoclast surface to bone surface within the trabecular region 
of the distal femora of Osx:Cre and EfnB1OB−/− sham and OVX mice (n = 4–5 samples/strain/condition). (G) 
Circulating collagen type I was measured by ELISA (n = 5–8 samples/strain/condition). All statistical analysis 
performed by 2-way ANOVA, multiple comparisons, *p ≤ 0.05. Magnification A–D = 10 µM.
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Figure 5. Mechanism of osteoclast function in human in vitro osteoclast differentiation assays. (A) Gene 
expression of Cathepsin K (CTSK) expressed as a fold increase compared to day 0 (n = 9 human donors, *p < 0.05, 
one-way ANOVA, multiple comparisons). (B) Expression profile of EphB receptors identified on human PBMNC 
prior to (Day 0) and under osteoclastogenic conditions (Day 7 and 14). (C–F) Human PBMNC placed under 
osteoclastic conditions in the presence of human IgG-Fc control or ephrinB1-Fc for 14 days were (C) stained for 
TRAP+ osteoclasts, (D) enumerated and represented as a percentage of TRAP+ multi-nucleated osteoclasts (OC) 
relative to the IgG-Fc control (n = 6 independent donors, *p < 0.05, Student t-test). (E,F) Samples were cultured 
for 21 days on Corning Osteo Assay Surface Muliple Well plates and (E) imaged. (F) The proportion of resorbed 
surface area was quantitated and represented as a percentage relative to the human IgG-Fc control (n = 3 human 
donors, *p < 0.05, Student t-test). (G–J) Samples cultured under osteoclastic conditions with ephrinB1-Fc in the 
presence of either the scramble peptide control (RTVA) or the EphB2-specific blocking peptide (SNEW). (G–H) 
On Day 14 samples were (G) stained for TRAP+ osteoclasts, (H) quantitated and represented as a percentage 
of TRAP+ OC relative to RTVA (n = 3 independent human donors, *p < 0.05, Student t-test). Resorptive 
function was assessed on day 21 of culture (I–J). Corning Osteo Assay plates were (I) imaged, (J) quantitated and 
represented as a percentage of resorption capacity relative to RTVA (n = 3 independent human donors, *p < 0.05, 
Student t-test). (K–N) Gene expression of (K) c-fms (L) Cathepsin K (CSTK), (M) RANK and (N) CXCR4 were 
analysed 7 or 14 days following osteoclast induction and represented as a percentage of gene expression when 
cultured in the presence of ephrinB1-Fc relative to human IgG (n = 2 human donors, *p < 0.05, Student t-test).
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treated EfnB1OB−/− mice, compared to sham Osx:cre control mice. Given the reported redundancy between EphB/ 
ephrinB family members, where ephrinB2/ EphB4 signaling within the osteogenic lineage has previously been 
shown to be important in the late stages of osteoblast differentiation10. Mice lacking ephrinB2 in osteoblasts 
exhibit delayed bone mineralization, significant reduction in bone stiffness, and a reduction in osteoblast dif-
ferentiation in the presence of parathyroid hormone39. Therefore, compensation by ephrinB2 reverse signalling 
in mature bone cells may be a contributing factor in preventing an exacerbated osteoporotic phenotype in OVX 
EfnB1OB−/− mice as has been suggested in other systems6,40,41. However, this is hypothesis requires furthermore 
investigation.
In the present study, both sham and OXV induced EfnB1OB−/− mice displayed higher osteoclast numbers 
compared to Osx:cre OVX-induced mice. These data are consistent with previous studies demonstrating that 
the loss of ephrinB1 by osteoprogenitors stimulated an increase in the number of osteoclasts during skeletal 
development12. The findings presented here suggest that ephrinB1 activation may act as a contact-dependent 
regulator of osteoclast differentiation. Importantly, histomorphometric analysis of the distal femur identified 
that OVX-induced EfnB1OB−/− mice exhibited a two-fold increase in the number of osteoclasts compared to 
OVX Osx:cre mice, and a significant increase in resorption activity when compared to the sham Osx:cre mice. It 
is therefore plausible that ephrinB1, expressed by osteoblasts, interacts with an Eph receptor expressed by mono-
cytes/osteoclast progenitors to inhibit osteoclast formation and activity. While Zhao and colleagues have reported 
that ephrinB1 and ephrinB2 are expressed by osteoclasts, but lack EphB expression6, other studies have reported 
that low levels of EphB receptors are expressed by murine osteoclasts42. However, it has been shown that EphB4 
indirectly suppresses osteoclast differentiation by inhibiting RANKL production on osteoblasts10. Importantly, 
the study showed that the direct delivery of EphB4 inhibitor (sEphB4) did not influence osteoclast production, 
demonstrating that EphB4 was not required for osteoclast formation. Rather administration of sEphB4, during 
co-culture of osteoblasts and osteoclast precursors was required to inhibit EphB4 on osteoblasts; which subse-
quently enhanced RANKL production and therefore osteoclast formation10. However, these studies have been 
conducted on mouse primary cells or cell lines.
The present study, sought to determine whether the role of EphB/ephrinB1 signaling during osteoclast dif-
ferentiation was similar between human samples, and that observed in the ephrinB1 mouse knockout studies. 
Our observations showed that EphB receptors were expressed by human peripheral blood mononuclear cells and 
differentiated osteoclasts. The expression of EphB2, the high affinity receptor for ephrinB1, was down-regulated 
during osteoclast differentiation. Functional studies found that stimulation of human peripheral blood mono-
cytes (osteoclast precursors) with soluble ephrinB1-Fc, inhibited TRAP+ multinucleated osteoclast formation, 
function and associated gene expression, compared to the human-IgG control. To confirm that ephrinB1 medi-
ated its inhibitory function through EphB2 expressing osteoclast precursors, an EphB2-specific blocking peptide 
was utilised. This peptide functions by competing with the ephrin ligand to bind to the ligand binding domain 
of EphB235. The addition of the EphB2 blocking peptide reversed the inhibition of osteoclast formation in the 
presence of ephrinB1-Fc. As previously mentioned, osteoclasts and their precursors also express ephrinB lig-
ands6, and it is therefore plausible to suggest that osteoclast precursors may interact with each other to mediate 
EphB2-ephrinB1 signalling. However, when hPBMNC were cultured under osteoclast conditions in the pres-
ence of the EphB2 blocking peptide but in the absence of ephrinB1-Fc, there was no significant difference in the 
number of TRAP + osteoclasts enumerated when compared to the scramble peptide control (data not shown). 
This observation is consist with previous studies investigating ephrinB2-EphB4 communication between oste-
oclasts using the EphB4 inhibitor10. Collectively, these observations suggest that the communication between 
EphB2-ephrinB1 within the osteoclast precursor population is not sufficient to activate EphB2 signalling. Rather, 
this study proposes that ephrinB1 expressing osteogenic cells directly interact with and activate EphB2 express-
ing osteoclast precursors to inhibit osteoclast differentiation. The findings confirm that EphB2/ephrinB1 sig-
naling during osteoclast differentiation is conserved between mouse and human. Where the loss of ephrinB1 
by osteoblasts in EfnB1OB−/− mice, enhanced osteoclast function, while the administration of ephrinB1 during 
osteoclast differentiation of human PBMNC inhibited osteoclast formation and function. Therefore, ephrinB1 
appears to act as a negative regulator of osteoclast formation via EphB2 forward signaling. This is consistent with 
the reported role of EphA4, which negatively regulates osteoclast resorption activity43. In contrast, interactions 
between EphA2/ephrinA2, have been reported to enhance osteoclast differentiation, while suppressing osteoblast 
differentiation44. Therefore, different Eph/ ephrin pairings may provide alternate mechanisms to “fine tune” dif-
ferent phases of bone remodelling during normal bone homeostasis or under pathological conditions.
Collectively, these findings demonstrate the importance of ephrinB1 signalling in maintaining healthy bone, 
where loss of ephrinB1 in osteoprogenitors not only perturbs osteoblast function, but also affects osteoclast for-
mation. Future studies are required to identify the downstream signaling pathways and mechanism activating 
osteoclast formation and function in response to EphB2-ephrinB1 signalling between the osteoclastic-osteogenic 
populations.
Data Availability Statement. All data generated or analysed during this study are included in this pub-
lished article.
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